STOK
Stoke Therapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 18 to Mar 20 ▼ 3 days of insider sells: $744.8K by 4 insiders, avg $32.17
- May 1 ▼ 1 insider sell $73.5K at $32.79
- Jun 1 ▼ 1 insider sell $54.9K at $30.58
- Jun 16 ▼ 1 insider sell $43.6K at $29.95
- Jul 1 ▼ 1 insider sell $236.1K at $32.66
- Jul 13 Goldman Sachs initiates
- Aug 3 ▼ 1 insider sell $208.4K at $29.04
- Aug 18 ▼ 3 insiders sell $646.9K at $32.03
- Sep 1 ▼ 1 insider sell $170.1K at $30.67
- Oct 1 to Oct 2 ▼ 2 days of insider sells: $44.0K by 2 insiders, avg $26.22
- Oct 21 ▼ Director Edward M. Kaye, MD, filed a Form 144 on October 21, 2026, i…
- Nov 2 ▼ 1 insider sell $189.9K at $26.39
Signal stack
Where each data set points today.
- InsidersBEARISH
5 insiders sold $2.5M.
- InstitutionsMIXED
Q3 2026: 20 added (0 new), 14 trimmed or exited.
- EstimatesFALLING
Current-quarter EPS estimate −$0.973 → −$1.186 over 90 days. 1 up, 2 down in 30 days.
- Short sellersSTEADY
Short interest +4.5% to 10.72M shares. 6.8 days to cover, ≈16.4% of shares.
- TrendUPTREND
1% above its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 29.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| UBS Group AG | ADD | $6.9M |
| FRANKLIN TEMPLETON INC | ADD | $5.5M |
| VICTORY CAPITAL MANAGEMENT INC | DOUBLED | $2.8M |
| TD ASSET MANAGEMENT INC | ADD | $2.6M |
| ALPS ADVISORS INC | ADD | $2.2M |
| FIRST TRUST ADVISORS LP | NEAR_EXIT | $1.6M |
| JANE STREET GROUP, LLC | NEAR_EXIT | $1.6M |
| Rafferty Asset Management, LLC | ADD | $1.5M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Aug 2026Price is below the lowest target. Median implies +61%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Aug 4, 2026 | Guggenheim REITERATE | Buy |
| Aug 4, 2026 | Wedbush MAINTAIN | Outperform |
| Aug 4, 2026 | Canaccord Genuity MAINTAIN | Buy |
| Aug 4, 2026 | Chardan Capital MAINTAIN | Buy |
| Jul 13, 2026 | Goldman Sachs INITIATE | Buy |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Ticho Barry CHIEF MEDICAL OFFICER Nov 2, 2026 | SELL | $5.4K |
Ticho Barry CHIEF MEDICAL OFFICER Nov 2, 2026 | SELL | $184.5K |
Allan Jonathan GENERAL COUNSEL & CORP SEC Oct 2, 2026 | SELL | $16.5K |
Ticho Barry CHIEF MEDICAL OFFICER Oct 1, 2026 | SELL | $27.5K |
Cumbo Alexander Director Sep 23, 2026 | AWARD | 39,674 sh |
Ticho Barry CHIEF MEDICAL OFFICER Sep 1, 2026 | SELL | $49.7K |
Ticho Barry CHIEF MEDICAL OFFICER Sep 1, 2026 | SELL | $120.4K |
Allan Jonathan GENERAL COUNSEL & CORP SEC Aug 18, 2026 | SELL | $86.9K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$1.19 | -$1.34–-$1.08 | -22.2% | $7.4M |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | -$4.01 | -$4.29–-$3.89 | -10.8% | $34.7M |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
18 filings · 1 bullish · 4 bearish · 13 neutral- NEUTRAL SC 13G/ANov 16, 2026
Baker Bros. Advisors LP filed an amended Schedule 13G disclosing a 4.7% beneficial ownership stake in Stoke Therapeutics as of September 30, 2026, down from a prior stake.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
Wellington Management Group LLP filed an amended Schedule 13G disclosing a 7.3% beneficial ownership stake in Stoke Therapeutics as of September 30, 2026, down from a prior 9.9% stake reported by RTW Investments. The filing is passive under Rule 13d-1(b), indicating no activist intent.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
RTW Investments, LP filed an amended Schedule 13G disclosing a 9.9% beneficial ownership stake in Stoke Therapeutics as of September 30, 2026, up from a prior stake. The filing is passive (Rule 13d-1(b)), indicating no intent to influence control.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 13, 2026
Morgan Stanley filed an amended Schedule 13G disclosing a 4.9% beneficial ownership stake in Stoke…
Monitor for any further reductions by Morgan Stanley or other large institutional holders. The drop below 5% removes Morgan Stanley from future 13G filing requirements, reducing transparency into…
All STOK filing & press-release reports (18)
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 13, 2026
- SC 13G/A reportNov 5, 2026
- 8-K reportOct 29, 2026
- 144 reportOct 21, 2026
- SC 13G reportSep 30, 2026
- 8-K reportSep 25, 2026
- CLUSTER reportAug 18, 2026
- 8-K reportAug 3, 2026
- 424B5 reportAug 3, 2026
- 8-K reportJun 30, 2026
- 8-K reportMay 7, 2026
- DEFA14A reportApr 22, 2026
- 8-K reportApr 7, 2026
- CLUSTER reportMar 13, 2026
- CLUSTER reportMar 10, 2026